Sharps Compliance Revenue Increases 22% to $6.3 Million;

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Sharps Compliance Revenue Increases 22% to $6.3 Million; Achieves Net Income of $122,000 in Fiscal 2014 First Quarter
  • First quarter billings grew 24% to record $6.7 million led by measurable growth in targeted retail and professional markets
  • Sequential growth in quarterly billings of 33% driven by growth in retail and professional markets
  • Retail market billings up 59% over prior-year first quarter and up 22% over comparative trailing twelve month period
  • Professional market billings increase 47% over prior-year first quarter and up 31% over comparative trailing twelve month period from both solid traction from inside and online sales channel and joint-marketing alliance wins
  • Balance sheet remains solid with a cash balance of $15.3 million and working capital of $16.7 million

HOUSTON, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Sharps Compliance Corp. (Nasdaq: SMED ) ("Sharps" or the "Company"), a leading full-service provider of solutions for the cost-effective management of medical waste, used healthcare materials and unused dispensed medications, today reported financial results for the first quarter fiscal year 2014 ended September 30, 2013.

Revenue in the first quarter of fiscal 2014 was $6.3 million, up $1.1 million, or 21.7%, over revenue in the fiscal 2013 first quarter of $5.2 million. Net income for the fiscal 2014 first quarter was $0.1 million, or $0.01 per diluted share, compared with a net loss of $0.6 million, or ($0.04) per diluted share, for the corresponding prior-year period.

Customer billings, the Company's measure for performance and progress of the business, increased $1.3 million, or 23.6%, to $6.7 million compared with the prior-year period, driven by solid growth in billings to the Retail, Professional and Home Health Care markets. These were offset by lower billings to the Core Government market, as last year's first quarter benefitted from a $0.2 million stocking order placed by the US Department of Defense. On a sequential basis, customer billings increased $1.7 million, or 32.7%, compared with $5.1 million in the trailing fourth quarter of fiscal 2013. Significant growth over the trailing quarter was realized in the Retail and Professional markets. (See Reconciliation of Customer Billings to Revenue in the supplemental table included at the end of this release.)

David P. Tusa, President and Chief Executive Officer of Sharps, commented, "Our disciplined focus on sales to key targeted markets coupled with our commitment to customer service is beginning to pay dividends. Additionally, our efforts to increase awareness of the Company as a comprehensive provider of medical waste management services are beginning to resonate in the industry. We look to further increase our traction in all key markets through field, inside and web sales supported by continued and more aggressive marketing initiatives."

Focused sales and marketing initiatives continue to drive revenue

Professional market billings grew $0.5 million, or 46.9%, to $1.5 million in the first quarter of fiscal 2014. Sales to this market also grew $0.4 million, or 41.7%, over the trailing fourth quarter of fiscal 2013. The continuing growth in this market is a result of the Company's targeted telemarketing initiatives and promotional activities to educate doctors, dentists and veterinarians of the significant cost advantage and convenience of the Company's Sharps ® Recovery mailback system when compared with the traditional pick-up service for the small quantity generator sector. The Company's inside and online sales channel, which is focused primarily on the Professional market, realized a 42.0% increase in billings to $1.1 million in the fiscal 2014 first quarter from $0.8 million in the prior-year period. Additionally, the Professional market was positively impacted by joint marketing alliance-related business during the current quarter.

Retail market billings increased $0.7 million, or 58.6%, to $1.8 million, compared with the prior-year period. Billings to this market were up 165% over the trailing fiscal 2013 fourth quarter. The year-over-year and sequential increases were primarily due to the timing of orders related to the traditional flu shot season. Nonetheless, sales to this market are trending upward as demonstrated by a 22% increase in trailing twelve months' sales when compared with the prior-year's trailing twelve month period. While this market is traditionally volatile, quarter-by-quarter, due to variability in demand of the flu shot solutions, the expansion of retail pharmacies' health care services, in general, helps drive growth for the Company.

The Home Health Care market reflected solid growth over the prior year's quarter, increasing $0.2 million, or 11.8%, to $2.0 million. First quarter Assisted Living billings were $0.4 million, up 14.9% over the prior-year period, while Pharmaceutical market billings were up 7.7%, to $0.6 million compared with the prior-year period.

Steady operating performance

Gross margin improved to 37.1% in the first quarter of fiscal 2014 compared with gross margin of 30.1% in the fiscal 2013 first quarter. The improvement was driven by the leverage gained from higher revenue.

Selling, general and administrative (SG&A) expense was consistent at $2.1 million in the first quarter of both fiscal 2014 and 2013. The Company expects to incur a quarterly level of about $2.2 million to $2.4 million in SG&A expense over the next several quarters.

For the first quarter of fiscal 2014, the Company generated operating income of $0.1 million compared with an operating loss of $0.6 million in the same period of the prior year.

Earnings before interest, taxes, depreciation, and amortization, or EBITDA, was $0.4 million for the first quarter of fiscal 2014 compared with an EBITDA loss of $0.4 million in the same period of the prior fiscal year. Sharps believes that when used in conjunction with GAAP measures, EBITDA, which is a non-GAAP measure, provides additional information related to its operating performance. (See Reconciliation of Net Income (Loss) to EBITDA in the supplemental table included at the end of this release.)

Financial flexibility and a strong balance sheet

Cash and cash equivalents were $15.3 million at September 30, 2013 compared with $15.5 million at June 30, 2013. Working capital was $16.7 million at September 30, 2013, comparable with $16.6 million at the end of fiscal 2013. At September 30, 2013, stockholders' equity and total assets were $21.2 million and $26.4 million, respectively, compared with $21.1 million and $25.5 million, respectively, at June 30, 2013.

In January 2013, the Company's Board of Directors authorized a stock repurchase program for up to $3.0 million over a two-year period. During the quarter ended September 30, 2013, the Company repurchased 19,000 shares at an average price of $2.71 per share, for a total of approximately $52,000, bringing total shares repurchased under the program to 44,360 at a cost of $126,000.

Well positioned for growth and profitability

Mr. Tusa noted, "Our experienced, dedicated team is committed to growing into a much larger organization as we further penetrate the billion dollar medical waste and unused medication management market. I will be working closely with Brandon Beaver, our new Senior VP of Sales, to continue our sales growth momentum by focusing on our core Home Health Care, Assisted Living, Professional and Pharmaceutical manufacturer markets. We are in the process of adding quality field sales persons and expanding our inside sales initiative as part of the execution strategy to drive further growth and profitability."

First quarter fiscal year 2014 webcast and conference call

The Company will host a teleconference today beginning at 11:00 a.m. Eastern Time, during which management will review the financial and operating results for the period and discuss Sharps' corporate strategy and outlook. A question-and-answer session will follow.

The Sharps conference call can be accessed by dialing (201) 689-8560. The webcast can be monitored at www.sharpsinc.com . Webcast listeners will have the opportunity to submit questions to the speakers. Select questions will be summarized and addressed during the question-and-answer portion of the call.

A telephonic replay will be available from 2:00 p.m. ET the day of the teleconference until Wednesday, November 6, 2013. To listen to the archived call, dial (858) 384-5517, and enter conference ID number 420953. A transcript will also be posted to Sharps' website, once available.

About Sharps Compliance Corp.

Headquartered in Houston, Texas, Sharps Compliance is a leading full-service provider of comprehensive medical waste management services throughout North America. Its strategy is to capture a large part of the estimated $3.8 billion untapped market for its solutions by targeting the major agencies that are interrelated with this medical waste stream, including pharmaceutical manufacturers, home healthcare providers, retail pharmacies and clinics, the U.S. government and the professional market which is comprised of physicians, dentists and veterinary practices. The Company's flagship product, the Sharps ® Recovery System, is a comprehensive solution for the containment, transportation, treatment and tracking of medical waste and used healthcare materials. The Company has partnered with Daniels Sharpsmart in a joint marketing alliance to serve the entire U.S. medical waste market, addressing small and large quantity medical waste generators with highly cost-effective and compliant solutions. Its innovative offerings serve the needs of healthcare and physician's facilities, dental groups and veterinarians that have multi-site and multi-size locations.

More information on the Company and its products can be found on its website at: www.sharpsinc.com

Safe harbor statement

The information made available in this news release contains certain forward-looking statements which reflect Sharps Compliance Corp.'s current view of future events and financial performance. Wherever used, the words "estimate," "expect," "plan," "anticipate," "believe," "may" and similar expressions identify forward-looking statements. Any such forward-looking statements are subject to risks and uncertainties and the company's future results of operations could differ materially from historical results or current expectations. Some of these risks include, without limitation, the company's ability to educate its customers, development of public awareness programs to educate the identified consumer, customer preferences, the Company's ability to scale the business and manage its growth, the degree of success the Company has at gaining more large customer contracts, managing regulatory compliance and/or other factors that may be described in the company's annual report on Form 10-K, quarterly reports on Form 10-Q and/or other filings with the Securities and Exchange Commission. Future economic and industry trends that could potentially impact revenue and profitability are difficult to predict. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results, express or implied therein, will not be realized.

Non-GAAP measures

This release contains certain financial information not derived in accordance with generally accepted accounting principles ("GAAP"), including customer billings information, EBITDA and non-GAAP net income (loss) per share. The Company believes this information is useful to investors and other interested parties. Such information should not be considered as a substitute for any measure derived in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Reconciliation of this information to the most comparable GAAP measures is included as an attachment to this release.

FINANCIAL TABLES FOLLOW.

       
SHARPS COMPLIANCE CORP. AND SUBSIDIARIES  
Condensed Consolidated Statements of Operations  
(in thousands, except per share data)  
       
  Three-Months Ended
September 30, 
 
  (Unaudited)  
 
2013

2012
%
Change
       
Revenue  $ 6,273  $ 5,153 21.7%
       
Cost of revenue 3,948 3,601 9.6%
Gross profit 2,325 1,552 49.8%
Gross margin 37.1% 30.1%  
SG&A expense 2,079 2,080 0.0%
Depreciation and amortization 116 113 2.7%
       
Operating income (loss)  130  (641)  
Operating margin 2.1% (12.4%)  
Other income 5  8  
       
Income (loss) before income taxes  135  (633)  
Income tax expense  13 6  
Net income (loss)  $ 122  $ (639)  
       
Net income (loss) per share      
 Basic   $ 0.01  $ (0.04)  
 Diluted  $ 0.01  $ (0.04)  
       
Weighted Average Shares Outstanding      
 Basic 15,343 15,209  
 Diluted 15,366 15,209  
     
SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(in thousands)
     
  September 30,
2013
June 30,
2013
  (Unaudited)  
ASSETS:    
Current assets:    
Cash and cash equivalents   $ 15,337  $ 15,503
Restricted cash  111 111
Accounts receivable, net  3,695 2,595
Inventory  1,523 1,632
Prepaid and other current assets  640 583
Total current assets  21,306 20,424
Property, plant and equipment, net  4,382 4,440
Intangible assets, net  723 668
Total assets   $ 26,411  $ 25,532
     
     
LIABILITIES AND STOCKHOLDERS' EQUITY:    
Current liabilities:    
Accounts payable   $ 1,667  $ 1,085
Accrued liabilities  1,293 1,345
Deferred revenue 1,637 1,351
Total current liabilities  4,597 3,781
Long-term deferred revenue  582 579
Other long-term liabilities 11 102
Total liabilities  5,190 4,462
Stockholders' equity:    
Total stockholders' equity  21,221 21,070
Total liabilities and stockholders' equity  $ 26,411  $ 25,532
           
SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
Supplemental Customer Billing and Revenue Information
(unaudited) 
(in thousands)
           
   Three-Months Ended September 30, 
  2013 % Total 2012 $ Change % Change
BILLINGS BY MARKET:          
Home Health Care  $ 1,953 29.1%  $ 1,747  $ 206 11.8%
Retail  1,848 27.5%  1,165 683 58.6%
Professional  1,470 21.9%  1,001 469 46.9%
Pharmaceutical   605 9.0%  562 43 7.7%
Assisted Living  432 6.4%  376 56 14.9%
Core Government   153 2.3%  392  (239) (61.0%)
Other  251 3.7%  186 65 34.9%
Subtotal  6,712 100.0%  5,429  1,283 23.6%
GAAP Adjustment *  (439)    (276)  (163) 59.1%
Revenue Reported  $ 6,273    $ 5,153  $ 1,120 21.7%
           
           
* Represents the net impact of the revenue recognition adjustments to arrive at reported GAAP revenue.
Customer billings include all invoiced amounts for products shipped during the period reported.
GAAP revenue includes customer billings as well as numerous adjustments necessary to reflect, (i) the deferral of a portion of current period sales and (ii) recognition of certain revenue associated with product returned for treatment and destruction. The difference between customer billings and GAAP revenue is reflected in the Company's balance sheet as deferred revenue.
           
SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
Supplemental Customer Billing by Channel Information
(unaudited)
(in thousands)
           
   Three-Months Ended September 30,
  2013 % Total 2012 $ Change % Change
BILLINGS BY CHANNEL:          
Direct Sales  $ 2,445 36.4%  $ 1,765  $ 680 38.5%
Distributors  3,161 47.2%  2,885  276 9.6%
Inside and Online Sales  1,106 16.5%  779 327 42.0%
Total Billings By Channel  $ 6,712 100.0%  $ 5,429  $ 1,283 23.6%
     
SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
Supplemental Table to Reconcile Net Income (Loss) to EBITDA
(unaudited)
(in thousands)
     
  Three-Months Ended
September 30, 
  2013 2012
     
Net Income (loss)  $ 122  $ (639)
     
Income tax expense  13  6
Interest income  (5)  (8)
Depreciation and amortization  272  276
     
EBITDA  $ 402  $ (365)

The Company defines earnings before interest, taxes, depreciation and amortization ("EBITDA") as net income (loss), plus income tax (benefit) expense, interest (income) expense, and depreciation and amortization. Other companies may define EBITDA differently. EBITDA is presented because it is a financial measure that is frequently requested by third parties. However, EBITDA is not considered under generally accepted accounting principles as a primary measure of an entity's financial results, and accordingly, EBITDA should not be considered an alternative to operating income (loss), net income (loss), or cash flows as determined under generally accepted accounting principles and as reported by the Company.

     
SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
Supplemental Reconciliation of GAAP to Non-GAAP Net Income (Loss) per Share *
(unaudited)
(in thousands, except per share data)
     
  September 30,
  2013 2012
     
Net income (loss)  $ 122  $ (639)
Diluted net income (loss) per share  $ 0.01  $ (0.04)
     
Deferred Tax Valuation Allowance  $ (41)  $ 217
     
Adjusted Net Income (Loss)  $ 81  $ (422)
     
Adjusted diluted net income (loss) per share*  $ 0.01  $ (0.03)
     
* In accordance with U.S. generally accepted accounting principles (GAAP), reported net income (loss) per share includes the after-tax impact of the items identified in this table. The Company believes this information is useful to investors and other interested parties. Such information would not be considered as a substitute for any measure derived in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies.

Diana P. Diaz Sharps Compliance Corp. Vice President and Chief Financial Officer Phone: (713) 660-3547 Email: Deborah K. Pawlowski Kei Advisors LLC Investor Relations Phone: (716) 843-3908 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 41

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 37

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 36

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 32

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading

Top 5 Most Recently Viewed Articles

DCHFA Appoints Dr. Moreiça Allana-Kim Ortega for Strategic Leadership

Updated Category News Views 325

DCHFA Welcomes Dr. Moreiça Allana-Kim Ortega The District of Columbia Housing Finance Agency (DCHFA) has announced an exciting new direction by creating an Office of Strategic Planning and Performance, under the leadership of Dr. Moreiça Allana-Kim Ortega. This new office is aimed at enhancing the effectiveness of the agency by addressing the evolving needs of housing...

Continue Reading
Cboe Hits Milestone of 1,000 ETFs, Showcasing Growth Trend

Updated Category News Views 120

Cboe Achieves Major Milestone in ETF Listings Cboe Global Markets, Inc. (Cboe: CBOE) has achieved a remarkable feat by surpassing 1,000 U.S.-listed exchange-traded funds (ETFs). This notable accomplishment underscores Cboe's position as a premier venue for innovative actively-managed ETFs. The exchange has welcomed an impressive number of 185 new U.S. ETFs this year,...

Continue Reading
Eat Happy Kitchen Expands Reach with Nationwide Kroger Partnership

Updated Category News Views 1256

Eat Happy Kitchen Expands Retail Presence Nationally In an exciting development for health-conscious shoppers, Eat Happy Kitchen has significantly expanded its reach across the U.S. Nearly 500 stores under the Kroger family umbrella will now feature the woman-owned brand's all-natural line of pasta sauces. This rapid expansion is a testament to the growing demand for...

Continue Reading
ThreeD Capital Reveals December Net Asset Value of $0.76

Updated Category News Views 183

Understanding ThreeD Capital's Recent NAV Announcement ThreeD Capital Inc. is a venture capital firm that carefully evaluates its financial standing to provide clarity to its stakeholders. Recently, the company disclosed that its unaudited net asset value (NAV) per share was valued at $0.76 as of December 31, 2024. This announcement reflects ThreeD’s commitment to...

Continue Reading
Innovative Wealth Planning Tool by Simon Quick Advisors Unveiled

Updated Category News Views 112

Simon Quick Advisors Introduces WealthMetrx™ for Tax Efficiency Simon Quick Advisors, a leading independent wealth management firm, has unveiled a new service called WealthMetrx™. This innovative approach aims to offer clients a comprehensive understanding of their tax profile by transforming intricate data into practical insights. With WealthMetrx™, clients can...

Continue Reading